Oral Abstracts (Abstracts 1–288)
1 October 2019
Issue Information
1 October 2019
Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease
Z. Gordon Jiang, Elliot B. Tapper – 1 October 2019
Author Index
1 October 2019
LiverLearning®: 2019 Webinar: Overview of Transplantation for Acute on Chronic Liver Failure - Webinar
In the first part of the webinar, we will provide an overview regarding the definitions of acute-on-chronic liver failure and the management of the cirrhotic patient with multi-organ system failure.
Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice
Yunhuan Liu, Kefei Chen, Fengyuan Li, Zelin Gu, Qi Liu, Liqing He, Tuo Shao, Qing Song, Fenxia Zhu, Lihua Zhang, Mengwei Jiang, Yun Zhou, Shirish Barve, Xiang Zhang, Craig J. McClain, Wenke Feng – 30 September 2019
Letter to the Editor: Methodological Issues Regarding the Matching in Matched Case‐Control Study
Amir Almasi‐Hashiani, Mohammad Ali Mansournia – 30 September 2019
Reply
Sung‐Hsi Huang, Chia‐Jui Yang, Chien‐Ching Hung – 30 September 2019
Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol
Christian Labenz, Jürgen H. Prochaska, Yvonne Huber, Michael Nagel, Beate K. Straub, Philipp Wild, Peter R. Galle, Jörn M. Schattenberg – 30 September 2019 – Cardiovascular disease (CVD) is the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). The current analysis expands the knowledge on atherogenic lipid profiles in NAFLD by modeling changes in low‐density lipoprotein cholesterol (LDL‐C) and total cholesterol (TC) in a prospectively enrolling real‐life study cohort to inform physicians on the cardiovascular (CV) event risk based on these changes.